Adjustable intragastric balloons: a 12-month pilot trial in endoscopic weight loss management

Evzen Machytka, Pavel Klvana, Asher Kornbluth, Steven Peikin, Lisbeth E M Mathus-Vliegen, Christopher Gostout, Gontrand Lopez-Nava, Scott Shikora, Jeffrey Brooks, Evzen Machytka, Pavel Klvana, Asher Kornbluth, Steven Peikin, Lisbeth E M Mathus-Vliegen, Christopher Gostout, Gontrand Lopez-Nava, Scott Shikora, Jeffrey Brooks

Abstract

Intragastric balloons are associated with (1) early period intolerance, (2) diminished effect within 3-4 months, and (3) bowel obstruction risk mandating removal at 6 months. The introduction of an adjustable balloon could improve comfort and offer greater efficacy. A migration prevention function, safely enabling prolonged implantation, could improve efficacy and weight maintenance post-extraction. The first implantations of an adjustable balloon with an attached migration prevention anchor are reported. The primary endpoint was the absence of bowel perforation, obstruction, or hemorrhage. Eighteen patients with mean BMI of 37.3 were implanted with the Spatz Adjustable Balloon system (ABS) for 12 months. Balloon volumes were adjusted for intolerance or weight loss plateau. Mean weight loss at 24 weeks was 15.6 kg with 26.4% EWL (percent of excess weight loss) and 24.4 kg with 48.8% EWL at 52 weeks. Sixteen adjustments were successfully performed. Six downward adjustments alleviated intolerance, yielding additional mean weight loss of 4.6 kg. Ten upward adjustments for weight loss plateau yielded a mean additional weight loss of 7 kg. Seven balloons were removed prematurely. Complications necessitating early removal included valve malfunction (1), gastritis (1), Mallory-Weiss tear (1), NSAID (2× dose/2 weeks) perforating ulcer (1), and balloon deflation (1). Two incidents of catheter shear from the chain: one passed uneventfully and one caused an esophageal laceration without perforation during extraction. The Spatz ABS has been successfully implanted in 18 patients. (1) Upward adjustments yielded additional weight loss. (2) Downward adjustments alleviated intolerance, with continued weight loss. (3) Preliminary 1-year implantation results are encouraging.

Figures

Fig. 1
Fig. 1
Inflated balloon without stabilizer band (deployed state in gastric lumen)
Fig. 2
Fig. 2
Insertion assembly without stabilizer band
Fig. 3
Fig. 3
Balloon with stabilizer band (arrow)
Fig. 4
Fig. 4
Insertion assembly with stabilizer band (arrow)

References

    1. Mathus-Vliegen EM. Intragastric balloon treatment for obesity: what does it really offer? Dig Dis. 2008;26(1):40–4. doi: 10.1159/000109385.
    1. Imaz I, Martínez-Cervell C, García-Alvarez EE, et al. Safety and effectiveness of the intragastric balloon for obesity. A meta-analysis. Obes Surg. 2008;18(7):841–6. doi: 10.1007/s11695-007-9331-8.
    1. Bonazzi P, Petrelli MD, Lorenzini I, et al. Gastric emptying and intragastric balloon in obese patients. Eur Rev Med Pharmacol Sci. 2005;9(5 Suppl 1):15–21.
    1. Mion F, Napoléon B, Roman S, et al. Effects of intragastric balloon on gastric emptying and plasma ghrelin levels in non-morbid obese patients. Obes Surg. 2005;15(4):510–6. doi: 10.1381/0960892053723411.
    1. Evans JD, Scott MH. Intragastric balloon in the treatment of patients with morbid obesity. Br J Surg. 2001;88(9):1245–8. doi: 10.1046/j.0007-1323.2001.01840.x.
    1. Sallet JA, Marchesini JB, Paiva DS, et al. Brazilian multicenter study of the intragastric balloon. Obes Surg. 2004;14(7):991–8. doi: 10.1381/0960892041719671.
    1. Genco A, Cipriano M, Bacci V, et al. BioEnterics Intragastric Balloon (BIB): a short-term, double-blind, randomized, controlled, crossover study on weight reduction in morbidly obese patients. Int J Obes (Lond) 2006;30(1):129–33. doi: 10.1038/sj.ijo.0803094.
    1. Doldi SB, Micheletto G, Perrini MN, et al. IGB; another option for treatment of obesity and morbid obesity. Hepatogastroenterology. 2004;51(55):294–7.
    1. Roman S, Napoleon B, Mion F, et al. IGB for non-morbid obesity: a retrospective evaluation of tolerance and efficacy. Obes Surg. 2004;14(4):539–44. doi: 10.1381/096089204323013587.
    1. Doldi SB, Micheletto G, Di Prisco F, et al. IGB in obese patients. Obes Surg. 2000;10(6):578–81. doi: 10.1381/096089200321594200.
    1. Al-Momen A, El-Mogy I. IGB for obesity; a retrospective evaluation of tolerance and efficacy. Obes Surg. 2005;15(1):101–5. doi: 10.1381/0960892052993558.
    1. Herve J, Wahlen CH, Schaeken A, et al. What becomes of patients 1 year after the IGB has been removed? Obes Surg. 2005;15(6):864–70. doi: 10.1381/0960892054222894.
    1. Melissas J, Mouzas J, Filis D, et al. The IGB—smoothing the path to bariatric surgery. Obes Surg. 2006;16(7):897–902. doi: 10.1381/096089206777822188.
    1. Busetto L, Segato G, De Luca M, et al. Preoperative weight loss by IGB in super obese patients treated with laparoscopic gastric banding: a case control study. Obes Surg. 2004;14(5):671–6. doi: 10.1381/096089204323093471.
    1. Doldi SB, Micheletto G, Perrini MN, et al. Treatment of morbid obesity with IGB in association with diet. Obes Surg. 2002;12(4):583–7. doi: 10.1381/096089202762252398.
    1. Totte E, Hendrickx L, Pauwels M, et al. Weight reduction by means of an intragastric device; experience with BIB. Obes Surg. 2001;11(4):519–23. doi: 10.1381/096089201321209459.
    1. Gaggiotti G, Tack J, Garrido AB, Jr, et al. Adjustable totally implantable intragastric prosthesis (ATIIP)-Endogast for treatment of morbid obesity: one-year follow-up of a multicenter prospective clinical survey. Obes Surg. 2007;17(7):949–56. doi: 10.1007/s11695-007-9174-3.
    1. Alfalah H, Philippe B, Ghazal F, et al. Intragastric balloon for preoperative weight reduction in candidates for laparoscopic gastric bypass with massive obesity. Obes Surg. 2006;16(2):147–50. doi: 10.1381/096089206775565104.
    1. Vandenplas Y, Bollen P, De Langhe K, et al. Intragastric balloons in adolescents with morbid obesity. Eur J Gastroenterol Hepatol. 1999;11(3):243–5. doi: 10.1097/00042737-199903000-00006.
    1. Al Kahtani K, Khan MQ, Helmy A, et al. Bio-enteric intragastric balloon in obese patients: a retrospective analysis of King Faisal Specialist Hospital experience. Obes Surg. 2010;20(9):1219–26. doi: 10.1007/s11695-008-9654-0.
    1. Weiner R, Gutberlet H, Bockhorn H. Preparation of extremely obese patients for laparoscopic gastric banding by gastric balloon therapy. Obes surg. 1999;9:261–4. doi: 10.1381/096089299765553133.
    1. Mui WL, Ng EK, Tsung BY, et al. Impact on obesity-related illnesses and quality of life following intragastric balloon. Obes Surg. 2010;20(8):1128–32. doi: 10.1007/s11695-008-9766-6.
    1. Lopez-Nava G, Angel Rubio M, Prados S, et al. BioEnterics® intragastric balloon (BIB®). Single ambulatory Spanish experience with 714 consecutive patients treated with one or two consecutive balloons. Obes Surg. 2011;21(1):5–9. doi: 10.1007/s11695-010-0093-3.
    1. Genco A, Cipriano M, Bacci V, et al. Intragastric balloon followed by diet vs. intragastric balloon followed by another balloon: a prospective study on 100 patients. Obes Surg. 2010;20(11):1496–500. doi: 10.1007/s11695-010-0231-y.
    1. Genco A, Bruni T, Doldi SB, et al. Bio enterics intragastric balloon: the italian experience with 2,515 patients. Obes Surg. 2005;15(8):1161–4. doi: 10.1381/0960892055002202.
    1. Martinez-Brocca MA, Belda O, Parejo J, et al. Intragastric balloon-induced satiety is not mediated by modification in fasting or postprandial plasma ghrelin levels in morbid obesity. Obes Surg. 2007;17(5):649–57. doi: 10.1007/s11695-007-9109-z.
    1. Ganesh R, Rao AD, Baladas HG, et al. The Bioenteric® Intragastric Balloon(BIB®) as a treatment for obesity: poor results in Asian patients. Singapore Med J. 2007;48(3):227.
    1. Mathus-Vliegen EM, Tytgat GN. Intragastric balloon for treatment-resistant obesity: safety, tolerance, and efficacy of 1-year balloon treatment followed by a 1-year balloon free follow up. Gastrointest Endosc. 2005;61:19–27. doi: 10.1016/S0016-5107(04)02406-X.
    1. Dastis NS, Francois E, Deviere J, et al. Intragastric balloon for weight loss: results in 100 individuals followed for at least 2.5 years. Endoscopy. 2009;41:575–80. doi: 10.1055/s-0029-1214826.
    1. Vanden Eynden F, Urbain P. Small intestine gastric balloon impaction treated by laparoscopic surgery. Obes Surg. 2001;11(5):646–8. doi: 10.1381/09608920160556913.
    1. Francica G, Giardiello C, Scarano F, et al. Ultrasound diagnosis of IGB complications in obese patients. Radiol Med (Torino) 2004;l08(4):380–4.
    1. Kim WY, Kirkpatrick UJ, Moody AP, et al. Large bowel impaction by the BIB necessitating surgical intervention. Ann R Coll Surg Engl. 2000;82(3):202–4.
    1. Crea N, Pata G, Della Casa D, et al. Improvement of metabolic syndrome following intragastric balloon: 1 year follow-up analysis. Obes Surg. 2009;19:1084–8. doi: 10.1007/s11695-009-9879-6.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe